Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

Alzheimer's Disease (C7)

Organizer(s): David M. Holtzman, Dora M. Kovacs and Cynthia A. Lemere
March 24 - 29, 2008
Keystone Resort · Keystone, Colorado
Abstract Deadline: November 26, 2007
Late Abstract Deadline: December 26, 2007
Scholarship Deadline: November 26, 2007
Early Registration Deadline: January 25, 2008

Supported by the Director's Fund

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this educational activity for a maximum of 28-35 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

To receive CME credits, mark the box on the registration form, and pay the additional $50.00.

This meeting took place in the 2008 season.

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
Aggregation of the amyloid ß peptide and tau in the brain are key events in Alzheimer’s disease (AD). The understanding of the cell biological processes that lead to Aß formation is advancing rapidly. The cellular release, transport, and clearance of Aß and how Aß influences tau are just beginning to be understood. Studies of pathogenesis and treatment of AD with cellular and animal models are promising. Recent data in humans indicates that fluid and imaging biomarkers for both clinical and pre-clinical AD may be possible. Several pivotal issues that remain are: (1) to develop a full understanding of APP, A beta, and tau biology; (2) to be able to predict AD prior to cognitive decline; and (3) to develop effective methods to prevent and treat AD. The goal of this meeting will be to provide a state of the art update of the genetic, molecular, cell biological, and translational aspects of AD. Integration of current and novel bench and translational science in this area should lead to new ideas and collaborations.

Monday, March 24
3:00 - 7:30 PM	Registration	Shavano Peak Foyer
6:30 - 7:30 PM	Refreshments	Shavano Peak Foyer
7:30 - 9:15 PM	Keynote Session	Red Cloud Peak
	Christian Haass, University of Munich The Process of Amyloid ß-Peptide generation: Normal and Disease Biology
	Dennis J. Selkoe, Harvard Medical School The End Game in Alzheimer’s Disease: Translating Molecular Mechanisms into Therapeutics
Tuesday, March 25
7:00 - 8:00 AM	Breakfast	Shavano/Torreys
8:00 - 11:00 AM	Clinical, Epidemiological, and Genetic Factors Relevant to AD and Related Disorders	Red Cloud Peak
	* David M. Holtzman, Washington University
	John C. Morris, Washington University Preclinical AD and PreMCI: The Future of Alzheimer Research
	Rudolph E. Tanzi, Massachusetts General Hospital The Continuing Search for Novel Alzheimer's Disease Genes

	Lenore J. Launer, National Institute on Aging Cardiovascular and Non-Genetic Risk Factors for AD
	Elizabeth H. Corder, Duke University Short Talk: Genetic Risk Profiles for Alzheimer’s Disease: Integration of APOE Genotype and Variants that Up-Regulate Inflammation
	Peter J. Hudson, Aviper, Pty., Ltd. Short Talk: Early Stage Alzheimer’s Disease Diagnosis in a Unique Progressing Cohort by Correlation of Cognition, Neuroimaging and Blood Biomarkers (the AIBL Cluster Study).
9:20 - 9:40 AM	Coffee Break	Shavano Peak Foyer
11:00 AM - 1:00 PM	Poster Setup	Shavano/Torreys
1:00 - 10:00 PM	Poster Viewing	Shavano/Torreys
4:30 - 5:00 PM	Coffee Available	Shavano Peak Foyer
5:00 - 7:00 PM	APP Processing, Function, and Cell Biology of Neurodegeneration	Red Cloud Peak
	* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School
	Huaxi Xu, Burnham Institute for Medical Research Pathophysiological Functions of APP: A Potential Function of APP Metabolite AICD in EGFR Signaling and Apoptotic Neuronal Cell Death
	Gopal Thinakaran, University of Chicago APP Processing in Lipid Rafts
	Hui Zheng, Baylor College of Medicine Role of APP in Synaptic Structure and Function
	Patricia V. Burgos, NICHD, National Institutes of Health Short Talk: The AP4 Complex Mediates Sorting of the Amyloid Precursor Protein at the trans-Golgi Network
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Shavano/Torreys
7:30 - 10:00 PM	Poster Session 1	Shavano/Torreys
Wednesday, March 26
7:00 - 8:00 AM	Breakfast	Shavano/Torreys
8:00 - 11:15 AM	Abeta Metabolism, CAA, and Blood-Brain-Barrier	Red Cloud Peak
	* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School

	Randall Bateman, Washington University School of Medicine APP/Abeta Synthesis and Clearance in Humans
	Mathias Jucker, Universität Tübingen Mouse Models of Cerebral Abeta and Non-Abeta Amyloid Angiopathies
	William E. Van Nostrand, Stony Brook University Tg-SwDI: A Mouse Model to Investigate Cerebral Microvascular Amyloid, Neuroinflammation, and Behavioral Deficits
	Donna M. Wilcock, Duke University Short Talk: Neurovascular Unit Changes are Observed in Association with Cerebral Amyloid Angiopathy in Several Mouse Models of Alzheimer’s Disease
	Bruce T. Lamb, Cleveland Clinic Foundation Short Talk: The Role of Inflammation and Beta-Amyloid Oligomers in Triggering Aberrant Neuronal Cell Cycle Events
9:20 - 9:40 AM	Coffee Break	Shavano Peak Foyer
11:15 AM - 1:00 PM	Poster Setup	Shavano/Torreys
1:00 - 10:00 PM	Poster Viewing	Shavano/Torreys
4:30 - 5:00 PM	Coffee Available	Shavano Peak Foyer
5:00 - 7:00 PM	BACE and Gamma-Secretase	Red Cloud Peak
	* David M. Holtzman, Washington University
	Michael S. Wolfe, Brigham and Women's Hospital, Harvard Medical School Biochemistry and Inhibition of Gamma-Secretase and Presenilin-like Proteases
	Takeshi Iwatsubo, University of Tokyo Structure and Function of the gamma-Secretase Complex
	Robert J. Vassar, Northwestern University Medical School The Role of BACE1 in Alzheimer's Disease
	Doo Yeon Kim, Harvard Medical School, Massachusetts General Hospital Short Talk: BACE1 and gamma-Secretase Regulate Voltage-Gated Sodium Channel Metabolism
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Shavano/Torreys
7:30 - 10:00 PM	Poster Session 2	Shavano/Torreys
Thursday, March 27
7:00 - 8:00 AM	Breakfast	Shavano/Torreys
8:00 - 11:15 AM	Tau Function and Dysfunction in AD and Related Disorders	Red Cloud Peak
	* David M. Holtzman, Washington University

	Kurt R. Brunden, University of Pennsylvania Tau Focused Drug Discovery for Alzheimer’s Disease and Related Tauopathies
	Fred Van Leuven, Experimental Genetics Group - KU Leuven Tau Phosphorylation and Tauopathy in Mouse Models: Amyloid Activates GSK3
	Karen Hsiao Ashe, University of Minnesota Toward Understanding the Molecular Basis of Tau-induced Memory Loss

	Erik D. Roberson, University of Alabama at Birmingham Tau and Neuronal Dysfunction
	Tudor Alexandru Fulga, Harvard Medical School Short Talk: Actin Cytoskeleton – A Critical Mediator of Neuronal Degeneration in Alzheimer Disease
	George S. Bloom, University of Virginia Short Talk: Tau-Dependent Microtubule Loss Induced by Pre-Fibrillar Beta-amyloid
9:20 - 9:40 AM	Coffee Break	Shavano Peak Foyer
11:15 AM - 1:00 PM	Poster Setup	Shavano/Torreys
1:00 - 10:00 PM	Poster Viewing	Shavano/Torreys
4:30 - 5:00 PM	Coffee Available	Shavano Peak Foyer
5:00 - 7:00 PM	Biomarkers and Imaging	Red Cloud Peak
	* David M. Holtzman, Washington University
	* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School
	Anne M. Fagan, Washington University School of Medicine CSF and Amyloid Imaging Biomarkers in AD
	Tony Wyss-Coray, Stanford University School of Medicine Plasma protein biomarkers for aging and Alzheimer's disease
	Reisa A. Sperling, Brigham & Women's Hospital, Harvard Medical School Functional and Molecular Imaging in Early AD
	Jessica Koenigsknecht-Talboo, Washington University Short Talk: Dynamic Imaging of Microglia and Abeta Deposition: Evidence of Rapid Responses Following Systemic Anti-Abeta Antibody Administration
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Shavano/Torreys
7:30 - 10:00 PM	Poster Session 3	Shavano/Torreys
Friday, March 28
7:00 - 8:00 AM	Breakfast	Shavano/Torreys
8:00 - 11:15 AM	Therapeutics	Red Cloud Peak
	* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School
	Ronald B. DeMattos, Lilly Research Laboratories Update on Active and Passive Immunotherapy

	Gerald Koelsch, CoMentis, Inc. Beta-Secretase Inhibitor CTS-21166 Reduces Plasma Abeta40 in Human Subjects


	JoAnne McLaurin, University of Toronto Novel Small Molecule Therapies for AD
	Takaomi C. Saido, RIKEN Brain Science Institute N-Terminal Modification of Amyloid-beta Peptide, AbetaX-42, in Alzheimer's Disease and Mouse Models
	Hans-Ulrich Demuth, Probiodrug Research Short Talk: Prevention of Abeta3(pE)-42 Formation: A New Causative Treatment Paradigm in AD
	Jonathan Thomas Megerian, Epix Pharmaceuticals Short Talk: Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer’s Disease
9:20 - 9:40 AM	Coffee Break	Shavano Peak Foyer
4:30 - 5:00 PM	Coffee Available	Shavano Peak Foyer
5:00 - 7:00 PM	Therapeutics II	Red Cloud Peak
	* David M. Holtzman, Washington University
	Steven L. Wagner, TorreyPines Therapeutics Modulation of the Gamma Secretase Enzyme Complex with Orally Bioavailable Small Molecules
	Frank M. La Ferla, University of California, Irvine Reversing age-dependent memory impairments in a transgenic model of Alzheimer disease
	William James Ray, Merck & Co. Inc. Targeting Pathways that Lead to the Accumulation of Amyloid
	Michael Bacher, Philipp-University Marburg Short Talk: Administration of CNI-1493 inhibits Aß accumulation, amyloid plaque formation, and cognitive deterioration in an animal model of Alzheimer’s disease
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Shavano/Torreys
8:00 - 11:00 PM	Entertainment	Shavano/Torreys
Saturday, March 29
	Departure

*Session Chair †Speaker invited, not yet responded.